Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer

Authors: Kyung A Kwon, Sung Hyun Kim, Sung Yong Oh, Suee Lee, Jin-Yeong Han, Kyeong Hee Kim, Ri Young Goh, Hong Jo Choi, Ki Jae Park, Mee Sook Roh, Hyo-Jin Kim, Hyuk-Chan Kwon, Jong Hoon Lee

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Angiogenesis is a multistep process in which many growth factors and cytokines have an essential role. Vascular endothelial growth factor (VEGF) is a potent angiogenic agent that acts as a specific mitogen for vascular endothelial cells through specific cell surface receptors. The interleukin-6 (IL-6) pathway is another mechanism linking angiogenesis to malignancy. C-reactive protein (CRP), a representative marker for inflammation, is known for its association with disease progression in many cancer types. The aim of this study was to determine preoperative serum levels of VEGF, IL-6, and CRP in colorectal carcinoma, and to correlate them with disease status and prognosis.

Methods

A 132 of 143 patients who underwent curative resection for colorectal cancer were enrolled in this study. 11 patients with resection margin positive were excluded. Factors considered in analysis of the relationship between VEGF, IL-6, and CRP and histological findings. Patient prognosis was investigated. Serum levels of VEGF and IL-6 were assessed using Enzyme-Linked Immuno-Sorbent Assay (ELISA), and CRP was measured using immunoturbidimetry.

Results

Median follow-up duration was 18.53 months (range 0.73-43.17 months) and median age of the patients was 62 years (range, 26-83 years). Mean and median levels of VEGF and CRP in colorectal cancer were significantly higher than in the normal control group; 608 vs. 334 pg/mL and 528 (range 122-3242) vs. 312 (range 16-1121) (p < 0.001); 1.05 mg/dL vs. 0.43 mg/dL and 0.22 (range 0.00-18.40) vs. 0.07 (range 0.02-6.94) (p = 0.002), respectively. However mean and median level of IL-6 in patients were not significantly higher than in control; 14.33 pg/mL vs. 5.65 pg/mL and 6.00 (range 1.02-139.17) vs. 5.30 (4.50-13.78) (p = 0.327). Although IL-6 and CRP levels were not correlated with other pathological findings, VEGF level was significantly correlated with tumor size (p = 0.012) and CEA (p = 0.038). When we established the cutoff value for VEGF (825 pg/mL), IL-6 (8.09 pg/mL), and CRP (0.51 mg/dL) by Receiver Operating Characteristic (ROC) curve, we noted that high VEGF levels tended to reduce overall survival (p = 0.053), but not significantly. However, IL-6 and CRP demonstrated no significance with regard to disease free survival (p = 0.531, p = 0.701, respectively) and overall survival (p = 0.563, p = 0.572, respectively). Multivariate analysis showed that VEGF (p = 0.032), CEA (p = 0.012), lymph node metastasis (p = 0.002), and TNM stage (p = 0.025) were independently associated with overall survival.

Conclusions

Preoperative serum VEGF and CRP level increased in colorectal cancer patients. High VEGF level has been proposed as a poor prognostic factor for overall survival in patients with colorectal cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Giatromanolaki A, Sivridis E, Koukourakis MI: Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol. 2006, 29 (4): 408-417. 10.1097/01.coc.0000221317.56731.4e.CrossRefPubMed Giatromanolaki A, Sivridis E, Koukourakis MI: Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol. 2006, 29 (4): 408-417. 10.1097/01.coc.0000221317.56731.4e.CrossRefPubMed
2.
go back to reference Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, et al: Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat. 2009, 41 (3): 122-131. 10.4143/crt.2009.41.3.122.CrossRefPubMedPubMedCentral Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, et al: Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat. 2009, 41 (3): 122-131. 10.4143/crt.2009.41.3.122.CrossRefPubMedPubMedCentral
3.
go back to reference Compton CC, Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004, 54 (6): 295-308. 10.3322/canjclin.54.6.295.CrossRefPubMed Compton CC, Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004, 54 (6): 295-308. 10.3322/canjclin.54.6.295.CrossRefPubMed
4.
go back to reference Folkman J: What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990, 82 (1): 4-6. 10.1093/jnci/82.1.4.CrossRefPubMed Folkman J: What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990, 82 (1): 4-6. 10.1093/jnci/82.1.4.CrossRefPubMed
5.
go back to reference Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 1995, 14 (4): 263-277. 10.1007/BF00690598.CrossRefPubMed Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 1995, 14 (4): 263-277. 10.1007/BF00690598.CrossRefPubMed
6.
go back to reference Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 1997, 79: 233-269.PubMed Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 1997, 79: 233-269.PubMed
7.
go back to reference Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995, 146 (5): 1029-1039.PubMedPubMedCentral Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995, 146 (5): 1029-1039.PubMedPubMedCentral
8.
go back to reference Reinmuth N, Parikh AA, Ahmad SA, Liu W, Stoeltzing O, Fan F, Takeda A, Akagi M, Ellis LM: Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech. 2003, 60 (2): 199-207. 10.1002/jemt.10258.CrossRefPubMed Reinmuth N, Parikh AA, Ahmad SA, Liu W, Stoeltzing O, Fan F, Takeda A, Akagi M, Ellis LM: Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech. 2003, 60 (2): 199-207. 10.1002/jemt.10258.CrossRefPubMed
9.
go back to reference Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999, 77 (7): 527-543. 10.1007/s001099900019.CrossRefPubMed Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999, 77 (7): 527-543. 10.1007/s001099900019.CrossRefPubMed
10.
go back to reference Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55 (18): 3964-3968.PubMed Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55 (18): 3964-3968.PubMed
11.
go back to reference Van Snick J: Interleukin-6: an overview. Annu Rev Immunol. 1990, 8: 253-278. 10.1146/annurev.iy.08.040190.001345.CrossRefPubMed Van Snick J: Interleukin-6: an overview. Annu Rev Immunol. 1990, 8: 253-278. 10.1146/annurev.iy.08.040190.001345.CrossRefPubMed
12.
go back to reference Sehgal PB: Regulation of IL6 gene expression. Res Immunol. 1992, 143 (7): 724-734. 10.1016/0923-2494(92)80011-9.CrossRefPubMed Sehgal PB: Regulation of IL6 gene expression. Res Immunol. 1992, 143 (7): 724-734. 10.1016/0923-2494(92)80011-9.CrossRefPubMed
13.
go back to reference Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996, 271 (2): 736-741. 10.1074/jbc.271.2.736.CrossRefPubMed Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996, 271 (2): 736-741. 10.1074/jbc.271.2.736.CrossRefPubMed
14.
go back to reference Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y: Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol. 2006, 12 (28): 4473-4477.CrossRefPubMedPubMedCentral Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y: Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol. 2006, 12 (28): 4473-4477.CrossRefPubMedPubMedCentral
15.
go back to reference Ballou SP, Lozanski G: Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992, 4 (5): 361-368. 10.1016/1043-4666(92)90079-7.CrossRefPubMed Ballou SP, Lozanski G: Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992, 4 (5): 361-368. 10.1016/1043-4666(92)90079-7.CrossRefPubMed
16.
go back to reference Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993, 82 (2): 513-520.PubMed Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993, 82 (2): 513-520.PubMed
17.
go back to reference Law DJ, Olschwang S, Monpezat JP, Lefrancois D, Jagelman D, Petrelli NJ, Thomas G, Feinberg AP: Concerted nonsyntenic allelic loss in human colorectal carcinoma. Science. 1988, 241 (4868): 961-965. 10.1126/science.2841761.CrossRefPubMed Law DJ, Olschwang S, Monpezat JP, Lefrancois D, Jagelman D, Petrelli NJ, Thomas G, Feinberg AP: Concerted nonsyntenic allelic loss in human colorectal carcinoma. Science. 1988, 241 (4868): 961-965. 10.1126/science.2841761.CrossRefPubMed
18.
go back to reference Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med. 1988, 319 (9): 525-532. 10.1056/NEJM198809013190901.CrossRefPubMed Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med. 1988, 319 (9): 525-532. 10.1056/NEJM198809013190901.CrossRefPubMed
19.
go back to reference Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N, et al: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer. 1998, 77 (6): 998-1002.CrossRefPubMedPubMedCentral Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N, et al: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer. 1998, 77 (6): 998-1002.CrossRefPubMedPubMedCentral
20.
go back to reference Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H, Imamura M: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 1998, 78 (10): 1379-1384.CrossRefPubMedPubMedCentral Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H, Imamura M: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 1998, 78 (10): 1379-1384.CrossRefPubMedPubMedCentral
21.
go back to reference Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, Ellis LM: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg. 1997, 132 (5): 541-546.CrossRefPubMed Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, Ellis LM: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg. 1997, 132 (5): 541-546.CrossRefPubMed
22.
go back to reference Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000, 6 (7): 2803-2807.PubMed Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000, 6 (7): 2803-2807.PubMed
23.
go back to reference Werther K, Christensen IJ, Brunner N, Nielsen HJ: Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol. 2000, 26 (7): 657-662. 10.1053/ejso.2000.0977.CrossRefPubMed Werther K, Christensen IJ, Brunner N, Nielsen HJ: Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol. 2000, 26 (7): 657-662. 10.1053/ejso.2000.0977.CrossRefPubMed
24.
go back to reference Werther K, Christensen IJ, Nielsen HJ: The association between preoperative concentration of soluble vascular endothelial growth factor, perioperative blood transfusion, and survival in patients with primary colorectal cancer. Eur J Surg. 2001, 167 (4): 287-292. 10.1080/110241501300091480.CrossRefPubMed Werther K, Christensen IJ, Nielsen HJ: The association between preoperative concentration of soluble vascular endothelial growth factor, perioperative blood transfusion, and survival in patients with primary colorectal cancer. Eur J Surg. 2001, 167 (4): 287-292. 10.1080/110241501300091480.CrossRefPubMed
25.
go back to reference Werther K, Christensen IJ, Nielsen HJ: Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer. 2002, 86 (3): 417-423. 10.1038/sj.bjc.6600075.CrossRefPubMedPubMedCentral Werther K, Christensen IJ, Nielsen HJ: Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer. 2002, 86 (3): 417-423. 10.1038/sj.bjc.6600075.CrossRefPubMedPubMedCentral
26.
go back to reference De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, et al: Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer. 2004, 100 (2): 270-278. 10.1002/cncr.11911.CrossRefPubMed De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, et al: Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer. 2004, 100 (2): 270-278. 10.1002/cncr.11911.CrossRefPubMed
27.
go back to reference Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C: Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res. 2008, 147 (1): 99-107. 10.1016/j.jss.2007.05.041.CrossRefPubMed Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C: Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res. 2008, 147 (1): 99-107. 10.1016/j.jss.2007.05.041.CrossRefPubMed
28.
go back to reference Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM: Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000, 7 (2): 133-138. 10.1007/s10434-000-0133-7.CrossRefPubMed Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM: Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000, 7 (2): 133-138. 10.1007/s10434-000-0133-7.CrossRefPubMed
29.
go back to reference Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol. 2002, 102 (2): 169-178. 10.1006/clim.2001.5163.CrossRefPubMed Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol. 2002, 102 (2): 169-178. 10.1006/clim.2001.5163.CrossRefPubMed
30.
go back to reference Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G: Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol. 2005, 11 (11): 1639-1643.CrossRefPubMedPubMedCentral Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G: Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol. 2005, 11 (11): 1639-1643.CrossRefPubMedPubMedCentral
31.
go back to reference Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC: Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988, 232 (2): 347-350. 10.1016/0014-5793(88)80766-X.CrossRefPubMed Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC: Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988, 232 (2): 347-350. 10.1016/0014-5793(88)80766-X.CrossRefPubMed
32.
go back to reference Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006, 94 (11): 1568-1571.PubMedPubMedCentral Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006, 94 (11): 1568-1571.PubMedPubMedCentral
33.
go back to reference Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003, 107 (3): 363-369. 10.1161/01.CIR.0000053730.47739.3C.CrossRefPubMed Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003, 107 (3): 363-369. 10.1161/01.CIR.0000053730.47739.3C.CrossRefPubMed
34.
go back to reference Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006, 15 (2): 381-384. 10.1158/1055-9965.EPI-05-0626.CrossRefPubMed Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006, 15 (2): 381-384. 10.1158/1055-9965.EPI-05-0626.CrossRefPubMed
35.
go back to reference Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, Terlecki G, Gamian A: Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med. 2008, 46 (3): 359-364. 10.1515/CCLM.2008.089.CrossRefPubMed Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, Terlecki G, Gamian A: Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med. 2008, 46 (3): 359-364. 10.1515/CCLM.2008.089.CrossRefPubMed
36.
go back to reference Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, Ridker PM: C-reactive protein and risk of breast cancer. J Natl Cancer Inst. 2007, 99 (11): 890-894. 10.1093/jnci/djk202.CrossRefPubMed Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, Ridker PM: C-reactive protein and risk of breast cancer. J Natl Cancer Inst. 2007, 99 (11): 890-894. 10.1093/jnci/djk202.CrossRefPubMed
37.
go back to reference Denizot Y, Fixe P, Liozon E, Praloran V: Serum interleukin-8 (IL-8) and IL-6 concentrations in patients with hematologic malignancies. Blood. 1996, 87 (9): 4016-4017.PubMed Denizot Y, Fixe P, Liozon E, Praloran V: Serum interleukin-8 (IL-8) and IL-6 concentrations in patients with hematologic malignancies. Blood. 1996, 87 (9): 4016-4017.PubMed
38.
go back to reference Nozoe T, Matsumata T, Sugimachi K: Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol. 2000, 23 (3): 263-266.CrossRefPubMed Nozoe T, Matsumata T, Sugimachi K: Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol. 2000, 23 (3): 263-266.CrossRefPubMed
39.
go back to reference Nozoe T, Matsumata T, Kitamura M, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998, 176 (4): 335-338. 10.1016/S0002-9610(98)00204-9.CrossRefPubMed Nozoe T, Matsumata T, Kitamura M, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998, 176 (4): 335-338. 10.1016/S0002-9610(98)00204-9.CrossRefPubMed
40.
go back to reference McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG, McArdle CS: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg. 1995, 170 (4): 319-322. 10.1016/S0002-9610(99)80296-7.CrossRefPubMed McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG, McArdle CS: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg. 1995, 170 (4): 319-322. 10.1016/S0002-9610(99)80296-7.CrossRefPubMed
Metadata
Title
Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer
Authors
Kyung A Kwon
Sung Hyun Kim
Sung Yong Oh
Suee Lee
Jin-Yeong Han
Kyeong Hee Kim
Ri Young Goh
Hong Jo Choi
Ki Jae Park
Mee Sook Roh
Hyo-Jin Kim
Hyuk-Chan Kwon
Jong Hoon Lee
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-203

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine